English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, September 8, 2021
阿诺医药宣布AN2025、AN0025与atezolizumab三联治疗晚期实体瘤1a期临床在美国完成首例患者给药
阿諾醫藥宣佈AN2025、AN0025與atezolizumab三聯治療晚期實體瘤1a期臨床在美國完成首例患者給藥
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
Thursday, July 15, 2021
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575